No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

DiA Imaging Analysis Collaborates with Intel Corporation to Accelerate Processing Time of its AI-based Cardiac Ultrasound Software in Hospitals

DiA Imaging Analysis Collaborates with Intel Corporation to Accelerate Processing Time of its AI-based Cardiac Ultrasound Software in Hospitals

Editor: What To Know

  • Our edge-to-cloud infrastructure technology supports rich data analysis environments like DiA Imaging Analysis was able to optimize the processing time of its AI-based models by over 40% percent when running on local hospital IT infrastructure based on Intel CPUs, without requiring the use of a discrete graphics processing unit (GPU) or integration of more complex IT  infrastructures.
  • By working with Intel, DiA Imaging Analysis was able to optimize the processing time of its AI-based models by over 40% percent when running on local hospital IT infrastructure based on Intel CPUs, without requiring the use of a discrete graphics processing unit (GPU) or integration of more complex IT  infrastructures.
  • Using an AI solution like LVivo  Seamless that automatically runs ‘behind the scenes' on hospital servers eliminates many manual and visual steps involved with both cardiac ultrasound view selection and measurement,” said Hila Goldman Aslan, CEO, and co-founder of DiA Imaging Analysis.

DiA Imaging Analysis Ltd, a leading global provider of AI-powered ultrasound analysis software, has teamed up with Intelto streamline artificial intelligence (AI) solutions used by echocardiography (Echo) labs. DiA’s AI-based software, LVivo Seamless™, automatically analyzes cardiac ultrasound images using the Intel® Distribution of OpenVINO™ toolkit, to optimize processing time by over 40% percent while maintaining accuracy.

The ability to view key cardiac measurements results quickly after each scan is vital to the Echo Lab workflow.

DiA Imaging Analysis LVivo Seamless™ algorithm runs automatically on cardiac ultrasound exams, selecting and analyzing the optimal cardiac views to generate key measurements that help identify clinical indications – that are otherwise difficult to find visually or manually. DiA’s solutions enable sonographers and cardiologists to analyze higher scan volumes in a quicker and reproducible way, optimizing their everyday workflows.

“Intel is committed to creating world-changing technology that helps advance patient care. Our edge-to-cloud infrastructure technology supports rich data analysis environments like DiA Imaging Analysis was able to optimize the processing time of its AI-based models by over 40% percent when running on local hospital IT infrastructure based on Intel CPUs, without requiring the use of a discrete graphics processing unit (GPU) or integration of more complex IT  infrastructures. LVivo Seamless, where time and accuracy are crucial elements,” said Alex Flores, Head of  Global Health Solutions at Intel Corporation.

By working with Intel, DiA Imaging Analysis was able to optimize the processing time of its AI-based models by over 40% percent when running on local hospital IT infrastructure based on Intel CPUs, without requiring the use of a discrete graphics processing unit (GPU) or integration of more complex IT  infrastructures.

“Every minute counts in a busy echocardiography environment. Using an AI solution like LVivo  Seamless that automatically runs ‘behind the scenes’ on hospital servers eliminates many manual and visual steps involved with both cardiac ultrasound view selection and measurement,” said Hila Goldman Aslan, CEO, and co-founder of DiA Imaging Analysis. “We are thrilled to work closely with Intel, leveraging AI to make the analysis of ultrasound images smarter, faster, and  more accessible.”


DiA Imaging Analysis is a leading provider of FDA-cleared and CE marked ultrasound AI  software solutions that automate the way clinicians use and analyze ultrasound scans. The company’s LVivo product line for cardiac and abdominal auto analysis allows clinicians with varying levels of ultrasound experience to automatically analyze ultrasound images on their ultrasound devices and healthcare IT systems with increased speed, efficiency, and accuracy.  DiA serves thousands of end-users worldwide.  

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy